Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 65
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Mov Disord ; 35(7): 1189-1198, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32353194

RESUMO

BACKGROUND: Neuroleptic drug-induced parkinsonism (NIP) is a leading cause of parkinsonism, particularly in aging. Based on abnormal dopamine transporter scan results, individuals displaying chronic NIP are often diagnosed with Lewy-body Parkinson's disease (PD), but this assumption needs further substantiation. OBJECTIVE: To quantitate the profile of striatal dopaminergic nerve terminal density in NIP relative to PD. METHODS: We used the positron emission tomography ligand [11 C](+)-dihydrotetrabenazine targeting vesicular monoamine transporter type 2 (VMAT2) binding sites and collected various clinical parameters (motor ratings, olfaction, polysomnography to document rapid eye movement sleep muscle activity, quantitative sensory testing for pain thresholds) possibly predicting binding results in patients older than age 50 living with schizophrenia spectrum disorders under long-term stable antipsychotic drug treatment, with (N = 11) or without (N = 11) chart documention of chronic NIP, and compared them to healthy volunteers (N = 11) and others medicated for PD (N = 12). RESULTS: Striatal VMAT2 binding was dichotomous in the NIP group between those with spared (N = 5) or low (N = 6) PD-like values. Striatal binding reduction in the low VMAT2-NIP group was asymmetric without the gradient of maximal involvement in the posterior putamen typical of PD. Anosmia was the only nonmotor parameter measured matching the abnormal striatal VMAT2 binding status. CONCLUSION: These preliminary observations suggest that striatal VMAT2 binding is abnormal in a fraction of chronic NIP cases and differs in spatial distribution from PD. The possibility of a drug-induced axonopathy and resultant synaptopathy, as well as the evolution of the binding deficit, warrant further longitudinal studies in a large cohort. © 2020 International Parkinson and Movement Disorder Society.


Assuntos
Antipsicóticos , Doença de Parkinson Secundária , Transtornos Parkinsonianos , Antipsicóticos/efeitos adversos , Corpo Estriado/metabolismo , Humanos , Pessoa de Meia-Idade , Transtornos Parkinsonianos/induzido quimicamente , Transtornos Parkinsonianos/diagnóstico por imagem , Tomografia por Emissão de Pósitrons , Proteínas Vesiculares de Transporte de Monoamina
2.
Can J Neurol Sci ; 47(6): 747-755, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32624027

RESUMO

Tardive dyskinesia (TD) is a delayed and potentially irreversible motor complication following chronic exposure to centrally acting dopamine receptor antagonists, mainly of the class of antipsychotics drugs. New generations of antipsychotic drugs reduced its mean prevalence to 20%, but it continues to mar the drug experience and social integration in a significant fraction of patients. The underlying molecular cascade remains elusive, explaining in part why TD management is so often difficult. Protocol variations between experimental laboratories and inter-species differences in the biological response to antipsychotic drugs have added layers of complexity. The traditional dopamine D2 receptor supersensitivity hypothesis was revisited in an experimental nonhuman primate model. Findings in the striatum revealed a strong upregulation of D3, not D2, receptors specific to dyskinetic animals, and indirect evidence suggestive of a link between overactivation of glycogen synthase kinase-3ß signaling and TD. New effective vesicular monoamine transporter type 2 inhibitors alleviating TD have been approved in the USA. They were integrated to an emerging stepwise treatment algorithm for troublesome TD, which also includes consideration for changes in the current antipsychotic drug regimen and recognition of potentially aggravating factors such as anticholinergic co-medications. These advances may benefit TD.


Assuntos
Antipsicóticos , Discinesia Tardia , Animais , Antipsicóticos/efeitos adversos , Antagonistas de Dopamina , Humanos , Discinesia Tardia/induzido quimicamente , Discinesia Tardia/tratamento farmacológico
3.
Mov Disord ; 34(5): 717-726, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30675935

RESUMO

BACKGROUND: Tardive dyskinesia is a delayed and potentially irreversible motor complication arising from chronic exposure to antipsychotic drugs. Interaction of antipsychotic drugs with G protein-coupled receptors triggers multiple intracellular events. Nevertheless, signaling pathways that might be associated with chronic unwanted effects of antipsychotic drugs remain elusive. In this study, we aimed to better understand kinase signaling associated with the expression of tardive dyskinesia in nonhuman primates. METHODS: We exposed capuchin monkeys to prolonged haloperidol (n = 10) or clozapine (n = 6) treatments. Untreated animals were used as controls (n = 6). Half of haloperidol-treated animals (5) developed mild tardive dyskinesia similar to that found in humans. Using Western blots and immunochemistry, we measured putamen total and phosphorylated protein kinase levels associated with canonical and noncanonical signaling cascades of G protein-coupled receptors. RESULTS: Antipsychotic drugs enhanced pDARPP-32 and pERK1/2, but no difference ws observed in phosphoprotein kinase levels between dyskinetic and nondyskinetic monkeys. On the other hand, comparison of kinase levels between haloperidol-treated dyskinetic and nondyskinetic monkeys indicated that dyskinetic animals had lower GRK6 and ß-arrestin2 levels. Levels of pAkt and pGSK-3ß were also reduced, but only haloperidol-treated monkeys that developed tardive dyskinesia had reduced pGSK-3ß levels, whereas pAkt levels in dyskinetic animals positively correlated with dyskinetic scores. Interestingly, double immunofluorescence labeling showed that putamen dopamine D3 receptor levels were upregulated and that D3/pAkt colocalization was enriched in haloperidol-treated animals displaying tardive dyskinesia. CONCLUSIONS: Our results suggest that upregulation of putamen dopamine D3 receptor and alterations along the noncanonical GRK6/ß-arrestin2/Akt/GSK-3ß molecular cascade are associated with the development of tardive dyskinesia in nonhuman primates. © 2019 International Parkinson and Movement Disorder Society.


Assuntos
Clozapina/farmacologia , Glicogênio Sintase Quinase 3 beta/efeitos dos fármacos , Haloperidol/farmacologia , Proteínas Proto-Oncogênicas c-akt/efeitos dos fármacos , Putamen/efeitos dos fármacos , Discinesia Tardia/metabolismo , Animais , Cebus , Fosfoproteína 32 Regulada por cAMP e Dopamina/efeitos dos fármacos , Fosfoproteína 32 Regulada por cAMP e Dopamina/metabolismo , Quinases de Receptores Acoplados a Proteína G/efeitos dos fármacos , Quinases de Receptores Acoplados a Proteína G/metabolismo , Glicogênio Sintase Quinase 3 beta/metabolismo , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Fosforilação , Proteínas Proto-Oncogênicas c-akt/metabolismo , Putamen/metabolismo , Receptores de Dopamina D3/efeitos dos fármacos , Receptores de Dopamina D3/metabolismo , Transdução de Sinais , beta-Arrestina 2/efeitos dos fármacos , beta-Arrestina 2/metabolismo
4.
J Microencapsul ; 35(5): 428-438, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30189763

RESUMO

Intumescent fire retardant (IFR) coatings are nowadays considered as the most effective flame retardant (FR) treatment. Nevertheless, the principal compound in an IFR system, ammonium polyphosphate (APP), is highly sensitive to moisture and IFR coating effectiveness decreases quickly. The main objective of this study is to encapsulate APP in a hybrid silica-based membrane by sol-gel process using alkoxysilane tetraethoxysilane (TEOS) and methyltriethoxysilane (MTES) precursor. The morphology and structure of APP and microencapsulated ammonium polyphosphate (MAPP) were assessed by scanning electron microscopy and Fourier transforms infrared spectroscopy (FTIR). X-ray photoelectron spectroscopy (XPS) results revealed that APP was well encapsulated inside the polysiloxane shells. The thermal degradation of APP and MAPP was evaluated by thermogravimetric analysis. At 800 °C, the MAPP had higher char residue (70.49 wt%) than APP (3.06 wt%). The hydrophobicity of MAPP increased significantly with the water contact angles up to 98°, in comparison to 20° for APP.


Assuntos
Compostos de Amônio/administração & dosagem , Retardadores de Chama/administração & dosagem , Polifosfatos/administração & dosagem , Dióxido de Silício/química , Cápsulas/química , Composição de Medicamentos/métodos , Interações Hidrofóbicas e Hidrofílicas , Transição de Fase , Silanos/química , Temperatura
5.
Br J Psychiatry ; 209(1): 76-83, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26250742

RESUMO

BACKGROUND: Tic disorders, in particular chronic tic disorder and Tourette syndrome, affect about 1% of the population. The current treatment of choice is pharmacological or behavioural, addressing tics or the premonitory urges preceding tic onset. AIMS: The current study reports an open trial evaluating the effectiveness of a cognitive psychophysiological treatment addressing Tourette-specific sensorimotor activation processes rather than the tic. METHOD: Forty-nine people with Tourette syndrome and 36 people with chronic tics completed 10 weeks of individual cognitive psychophysiological therapy. Outcome measures included two tic severity scales and psychosocial measures. RESULTS: Post-treatment both groups had significantly improved on the tic scales with strong effect sizes across tic locations and complex and simple tics, maintained at 6-month follow-up with further change in perfectionism and self-esteem. CONCLUSIONS: The cognitive psychophysiological approach targeting underlying sensorimotor processes rather than tics in Tourette's and chronic tic disorder reduced symptoms with a large effect size.


Assuntos
Terapia Cognitivo-Comportamental/métodos , Avaliação de Resultados em Cuidados de Saúde , Transtornos de Tique/terapia , Adulto , Feminino , Seguimentos , Humanos , Masculino , Síndrome de Tourette/terapia
6.
Lancet ; 393(10187): 2195-2196, 2019 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-31162073

Assuntos
Logro , Pesquisadores
8.
Exp Brain Res ; 233(9): 2707-21, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26055990

RESUMO

Evidence suggests that Parkinson's disease (PD) patients produce large spatial errors when reaching to proprioceptively defined targets. Here, we examined whether these movement inaccuracies result mainly from impaired use of proprioceptive inputs for movement planning mechanisms or from on-line movement guidance. Medicated and non-medicated PD patients and healthy controls performed three-dimensional reaching movements in four sensorimotor conditions that increase proprioceptive processing requirements. We assessed the influence of these sensorimotor conditions on the final accuracy and initial kinematics of the movements. If the patterns of final errors are primarily determined by planning processes before the initiation of the movement, the initial kinematics of reaching movements should show similar trends and predict the pattern of final errors. Medicated and non-medicated PD patients showed a greater mean level of final 3D errors than healthy controls when proprioception was the sole source of information guiding the movement, but this difference reached significance only for medicated PD patients. However, the pattern of initial kinematics and final spatial errors were markedly different both between sensorimotor conditions and between groups. Furthermore, medicated and non-medicated PD patients were less efficient than healthy controls in compensating for their initial spatial errors (hand distance from target location at peak velocity) when aiming at proprioceptively defined compared to visually defined targets. Considered together, the results are consistent with a selective deficit in proprioceptively based movement guidance in PD. Furthermore, dopaminergic medication did not improve proprioceptively guided movements in PD patients, indicating that dopaminergic dysfunction within the basal ganglia is not solely responsible for these deficits.


Assuntos
Movimento/fisiologia , Doença de Parkinson/complicações , Propriocepção/fisiologia , Transtornos de Sensação/etiologia , Idoso , Análise de Variância , Fenômenos Biomecânicos , Dopaminérgicos/farmacologia , Dopaminérgicos/uso terapêutico , Feminino , Mãos/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/tratamento farmacológico , Estimulação Luminosa , Propriocepção/efeitos dos fármacos , Desempenho Psicomotor/efeitos dos fármacos , Amplitude de Movimento Articular/efeitos dos fármacos , Amplitude de Movimento Articular/fisiologia , Transtornos de Sensação/tratamento farmacológico , Percepção Visual/efeitos dos fármacos , Percepção Visual/fisiologia
9.
Mov Disord ; 29(9): 1125-33, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24838395

RESUMO

Tardive dyskinesia (TD) is a delayed and potentially irreversible motor complication arising in patients chronically exposed to centrally active dopamine D2 receptor antagonists, including antipsychotic drugs and metoclopramide. The classical dopamine D2 receptor supersensitivity hypothesis in TD, which stemmed from rodent studies, lacks strong support in humans. To investigate the neurochemical basis of TD, we chronically exposed adult capuchin monkeys to haloperidol (median, 18.5 months; n = 11) or clozapine (median, 6 months; n = 6). Six unmedicated animals were used as controls. Five haloperidol-treated animals developed mild TD movements, and no TD was observed in the clozapine group. Using receptor autoradiography, we measured striatal dopamine D1, D2, and D3 receptor levels. We also examined the D3 receptor/preprotachykinin messenger RNA (mRNA) co-expression, and quantified preproenkephalin mRNA levels, in striatal sections. Unlike clozapine, haloperidol strongly induced dopamine D3 receptor binding sites in the anterior caudate-putamen, particularly in TD animals, and binding levels positively correlated with TD intensity. Interestingly, the D3 receptor upregulation was observed in striatonigral neurons. In contrast, D2 receptor binding was comparable to controls, and dopamine D1 receptor binding was reduced in the anterior putamen. Enkephalin mRNA widely increased in all animals, but to a greater extent in TD-free animals. These results suggest for the first time that upregulated striatal D3 receptors correlate with TD in nonhuman primates, adding new insights to the dopamine receptor supersensitivity hypothesis. The D3 receptor could provide a novel target for drug intervention in human TD.


Assuntos
Encéfalo/metabolismo , Transtornos dos Movimentos/fisiopatologia , Receptores de Dopamina D2/metabolismo , Receptores de Dopamina D3/metabolismo , Regulação para Cima/fisiologia , Animais , Antipsicóticos/farmacologia , Encéfalo/efeitos dos fármacos , Cebus , Clozapina/farmacologia , Modelos Animais de Doenças , Antagonistas de Dopamina/toxicidade , Encefalinas/genética , Encefalinas/metabolismo , Feminino , Haloperidol/toxicidade , Radioisótopos do Iodo/farmacocinética , Transtornos dos Movimentos/etiologia , Transtornos dos Movimentos/metabolismo , Transtornos dos Movimentos/patologia , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Ovariectomia , Ligação Proteica/efeitos dos fármacos , Receptores de Dopamina D2/genética , Receptores de Dopamina D3/genética , Sulpirida/análogos & derivados , Sulpirida/farmacocinética , Tetra-Hidronaftalenos/farmacocinética , Regulação para Cima/efeitos dos fármacos
10.
J Clin Psychopharmacol ; 34(1): 36-9, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24145218

RESUMO

OBJECTIVE: Parkinsonism (or Parkinson's syndrome [PS]) remains common in patients exposed to antipsychotic drugs. One clinical tool used in its detection and follow-up, the Simpson-Angus Scale (SAS), has been under revision lately. We further examined the discriminative power of the SAS to detect PS and its efficacy as a measure of PS intensity in chronic schizophrenia. METHODS: Fifty-six outpatients between 50 and 75 years of age, under stable antipsychotic drug therapy, provided consent to undergo an evaluation along the SAS and Unified Parkinson's Disease Rating Scale III motor subsection, split according to the presence or absence of PS defined in the UK Parkinson's Disease Society Brain Bank (UKPDSBB) criteria or Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria. RESULTS: The identification rate for PS was 39.3% based on UKPDSBB criteria applied to the Unified Parkinson's Disease Rating Scale III, compared with 62.5% and 87.5% according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and SAS cutoff value greater than 0.3, respectively. Median SAS scores for PS and PS-free participants were comparable. The SAS yielded high sensitivity (90.9%) but low specificity (17.7%). κ Values generally revealed only slight agreement between the group allocation provided by the SAS and the UKPDSBB criteria. Receiver operating characteristic curve for screening performance of the SAS provided poor prediction of subject status. CONCLUSIONS: The SAS lacks specificity and constitutes an imperfect detection and measurement tool for PS in older adults. Raising the cutoff score would avoid inflation in PS identification. The scale is probably best used as a measure of change relative to baseline score following an intervention, but results should be interpreted with caution.


Assuntos
Antipsicóticos/efeitos adversos , Atividade Motora/efeitos dos fármacos , Exame Neurológico , Transtornos Parkinsonianos/diagnóstico , Esquizofrenia/tratamento farmacológico , Fatores Etários , Idoso , Área Sob a Curva , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos Parkinsonianos/induzido quimicamente , Transtornos Parkinsonianos/fisiopatologia , Transtornos Parkinsonianos/psicologia , Valor Preditivo dos Testes , Psicometria , Curva ROC , Reprodutibilidade dos Testes , Fatores de Risco , Esquizofrenia/diagnóstico
11.
J Clin Med ; 13(9)2024 Apr 24.
Artigo em Inglês | MEDLINE | ID: mdl-38731020

RESUMO

Background/Objectives: Tourette Syndrome (TS), Obsessive Compulsive Disorder (OCD), and Body-Focused Repetitive Behaviors (BFRB) are three disorders that share many similarities in terms of phenomenology, neuroanatomy, and functionality. However, despite the literature pointing toward a plausible spectrum of these disorders, only a few studies have compared them. Studying the neurocognitive processes using Event-Related Potentials (ERPs) offers the advantage of assessing brain activity with excellent temporal resolution. The ERP components can then reflect specific processes known to be potentially affected by these disorders. Our first goal is to characterize 'when' in the processing stream group differences are the most prominent. The second goal is to identify 'where' in the brain the group discrepancies could be. Methods: Participants with TS (n = 24), OCD (n = 18), and BFRB (n = 16) were matched to a control group (n = 59) and were recorded with 58 EEG electrodes during a visual counting oddball task. Three ERP components were extracted (i.e., P200, N200, and P300), and generating sources were modelized with Standardized Low-Resolution Electromagnetic Tomography. Results: We showed no group differences for the P200 and N200 when controlling for anxiety and depressive symptoms, suggesting that the early cognitive processes reflected by these components are relatively intact in these populations. Our results also showed a decrease in the later anterior P300 oddball effect for the TS and OCD groups, whereas an intact oddball effect was observed for the BFRB group. Source localization analyses with sLORETA revealed activations in the lingual and middle occipital gyrus for the OCD group, distinguishing it from the other two clinical groups and the controls. Conclusions: It seems that both TS and OCD groups share deficits in anterior P300 activation but reflect distinct brain-generating source activations.

12.
J Clin Med ; 13(9)2024 Apr 24.
Artigo em Inglês | MEDLINE | ID: mdl-38731007

RESUMO

Background: Tourette syndrome (TS) and Chronic Tic Disorder (CT) are neurodevelopmental conditions involving motor and/or phonic tics. Youth with tics may encounter feelings of isolation, diminished self-esteem and quality of life, and academic difficulties. A growing body of scientific literature suggests sex differences in youth with tics, but findings have been mixed so far. Because symptom severity peaks around puberty, understanding sex differences in tic manifestations and associated symptoms during this critical period is essential. Therefore, we aimed to assess sex differences related to tic symptoms, action planning styles, quality of life, and externalizing/internalizing symptoms in youth with tics. Methods: Our sample consisted of 66 youths with tics (19 girls) aged 7-14 (mean = 10 years). Youths were assessed with clinical interviews, as well as self- and parent-reported inventories evaluating tic symptoms, psychological profiles, and quality of life. Results: While no differences in tic symptoms were found, girls exhibited lower functional inflexibility, reduced overall functional planning effectiveness, and higher impairment in the psychological well-being subscale than boys. Additionally, girls had reduced general life satisfaction and social self-esteem. Boys reported more explosive outbursts, higher levels of hyperactivity, and more difficulties with self-concept. Conclusions: Our analyses suggested differences in several manifestations associated with tics. This introduces new perspectives that refine our understanding of sex differences. A better understanding of sex differences in tic disorders may eventually improve outcomes for all individuals living with these conditions.

13.
J Clin Med ; 13(10)2024 May 18.
Artigo em Inglês | MEDLINE | ID: mdl-38792517

RESUMO

(1) Background: Gilles de la Tourette Syndrome (TS) is a neurodevelopmental disorder characterized by motor and vocal tics. Attention deficit and hyperactivity disorder (ADHD) is a common comorbidity of TS that adds further impairment. Cognitive-behavioural therapy (CBT) has shown efficacy in treating tics, yet its effectiveness in individuals with TS and comorbid ADHD remains unclear. Also, it is suggested that ADHD characteristics like executive dysfunction and inattention could hinder the response to CBT. This study aims to compare the response to CBT for tics and its maintenance six months post-therapy among TS individuals with and without ADHD symptoms. (2) Methods: In this study, 55 TS participants who completed 14-week CBT for tics were split into high (TS+) or low (TS-) ADHD symptomatology groups. Outcomes were evaluated using the Yale Global Tic Severity Scale (YGTSS) regarding global tic severity and motor and vocal tic frequency post-CBT and at a 6-month follow-up. (3) Results: No significant group difference was found regarding improvements post-CBT (n = 55), nor the maintenance six months later (n = 45). (4) Conclusions: ADHD symptoms may not hinder the response to CBT or its maintenance, suggesting that TS individuals with ADHD symptoms may not require specialized CBT interventions.

14.
Eur J Neurosci ; 38(1): 2192-8, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23551242

RESUMO

Tardive dyskinesia (TD) is a delayed and potentially irreversible motor complication arising in patients chronically exposed to antipsychotic drugs. As several modern (so-called atypical) antipsychotic drugs are common offenders, combined with the widening clinical indications for prescription as well as exposure of vulnerable individuals, TD will remain a significant drug-induced unwanted side effect. In addition, the pathophysiology of TD remains elusive and therapeutics are difficult. Based on rodent experiments, we have previously shown that the transcriptional factor Nur77 (also known as nerve growth factor inducible gene B or Nr4a1) is induced in the striatum following antipsychotic drug exposure as part of a long-term neuroadaptive process. To confirm this, we exposed adult capuchin (Cebus apella) monkeys to prolonged treatments with haloperidol (median 18.5 months, N = 11) or clozapine (median 6 months, N = 6). Six untreated animals were used as controls. Five haloperidol-treated animals developed mild TD movements similar to those found in humans. No TD was observed in the clozapine group. Postmortem analysis of Nur77 expression measured by in situ hybridization revealed a stark contrast between the two drugs, as Nur77 mRNA levels in the caudate-putamen were strongly upregulated in animals exposed to haloperidol but were spared following clozapine treatment. Interestingly, within the haloperidol-treated group, TD-free animals showed higher Nur77 expression in putamen subterritories compared with dyskinetic animals. This suggests that Nur77 expression might be associated with a reduced risk of TD in this experimental model and could provide a novel target for drug intervention.


Assuntos
Antipsicóticos/farmacologia , Corpo Estriado/metabolismo , Haloperidol/farmacologia , Transtornos dos Movimentos/metabolismo , Membro 1 do Grupo A da Subfamília 4 de Receptores Nucleares/metabolismo , Animais , Cebus , Clozapina/farmacologia , Corpo Estriado/efeitos dos fármacos , Feminino , Transtornos dos Movimentos/fisiopatologia , Membro 1 do Grupo A da Subfamília 4 de Receptores Nucleares/genética , Putamen/efeitos dos fármacos , Putamen/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Transcrição Gênica/efeitos dos fármacos , Regulação para Cima
15.
Brain Cogn ; 81(2): 271-82, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23313834

RESUMO

The capacity to learn new visuomotor associations is fundamental to adaptive motor behavior. Evidence suggests visuomotor learning deficits in Parkinson's disease (PD). However, the exact nature of these deficits and the ability of dopamine medication to improve them are under-explored. Previous studies suggested that learning driven by large and small movement errors engaged distinct neural mechanisms. Here, we investigated whether PD patients have a generalized impairment in visuomotor learning or selective deficits in learning from large explicit errors which engages cognitive strategies or small imperceptible movement errors involving primarily implicit learning processes. Visuomotor learning skills of non-medicated and medicated patients were assessed in two reaching tasks in which the size of visuospatial errors experienced during learning was manipulated using a novel three-dimensional virtual reality environment. In the explicit perturbation task, the visuomotor perturbation was applied suddenly resulting in large consciously detected initial spatial errors, whereas in the implicit perturbation task, the perturbation was gradually introduced in small undetectable steps such that subjects never experienced large movement errors. A major finding of this study was that PD patients in non-medicated and medicated conditions displayed slower learning rates and smaller adaptation magnitudes than healthy subjects in the explicit perturbation task, but performance similar to healthy controls in the implicit perturbation task. Also, non-medicated patients showed an average reduced deadaptation relative to healthy controls when exposed to the large errors produced by the sudden removal of the perturbation in both the explicit and implicit perturbation tasks. Although dopaminergic medication consistently improved motor signs, it produced a variable impact on learning the explicit perturbation and deadaptation and unexpectedly worsened performance in some patients. Considered together, these results indicate that PD selectively impairs the ability to learn from large consciously detected visuospatial errors. This finding suggests that basal ganglia-related circuits are important neural structures for adaptation to sudden perturbations requiring awareness and high-cost action selection. Dopaminergic treatment may selectively compromise the ability to learn from large explicit movement errors for reasons that remain to be elucidated.


Assuntos
Antiparkinsonianos/uso terapêutico , Cognição/fisiologia , Aprendizagem/fisiologia , Doença de Parkinson/fisiopatologia , Desempenho Psicomotor/fisiologia , Adaptação Fisiológica/efeitos dos fármacos , Adaptação Fisiológica/fisiologia , Idoso , Antiparkinsonianos/farmacologia , Fenômenos Biomecânicos/efeitos dos fármacos , Fenômenos Biomecânicos/fisiologia , Cognição/efeitos dos fármacos , Feminino , Humanos , Aprendizagem/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Movimento/efeitos dos fármacos , Movimento/fisiologia , Testes Neuropsicológicos , Doença de Parkinson/tratamento farmacológico , Desempenho Psicomotor/efeitos dos fármacos
16.
Sci Rep ; 13(1): 21955, 2023 Dec 11.
Artigo em Inglês | MEDLINE | ID: mdl-38082144

RESUMO

A novel sandwich-structured composite was developed from the surface layers of polyhydroxyalkanoate (PHA) and the interlayer of polylactic acid (PLA)/cellulose microfibers (CMF) composite. Moreover, CMF was chemically modified via a sol-gel process to improve the compatibility between the natural reinforcement and the polymer matrix. According to the obtained results, the modified CMF exhibited a highly hydrophobic characteristic (contact angel value of approximately 118°), and they were homogeneously dispersed in the PLA matrix. The results of the thermogravimetric analysis indicated that the sandwich composites reinforced with the modified CMF showed improvement in thermal stability. Regarding the mechanical properties, the incorporation of the natural reinforcement into sandwich composites increased the values of tensile modulus and strength of materials. The water vapor permeability of sandwich composites increased with the addition of untreated fibers; however, the composites reinforced with the modified CMF showed superior barrier performance than that of untreated CMF. In addition, a durability test was performed to determine the effect of accelerated aging on the properties of sandwich composites. The results demonstrated that the mechanical and barrier properties of composites incorporated with untreated CMF decreased after the accelerated aging, whereas the composites reinforced with the modified CMF experienced the least change.

17.
Behav Brain Funct ; 8: 12, 2012 Mar 09.
Artigo em Inglês | MEDLINE | ID: mdl-22404856

RESUMO

Tardive dyskinesia remains an elusive and significant clinical entity that can possibly be understood via experimentation with animal models. We conducted a literature review on tardive dyskinesia modeling. Subchronic antipsychotic drug exposure is a standard approach to model tardive dyskinesia in rodents. Vacuous chewing movements constitute the most common pattern of expression of purposeless oral movements and represent an impermanent response, with individual and strain susceptibility differences. Transgenic mice are also used to address the contribution of adaptive and maladaptive signals induced during antipsychotic drug exposure. An emphasis on non-human primate modeling is proposed, and past experimental observations reviewed in various monkey species. Rodent and primate models are complementary, but the non-human primate model appears more convincingly similar to the human condition and better suited to address therapeutic issues against tardive dyskinesia.


Assuntos
Antipsicóticos/efeitos adversos , Transtornos dos Movimentos/fisiopatologia , Animais , Modelos Animais de Doenças , Humanos , Camundongos , Camundongos Transgênicos , Transtornos dos Movimentos/psicologia , Transtornos dos Movimentos/terapia , Primatas , Ratos
18.
Materials (Basel) ; 14(15)2021 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-34361503

RESUMO

This study focuses on the development of advanced water-resistant bio-based membranes with enhanced vapour permeability for use within building envelopes. Building walls are vulnerable to moisture damage and mold growth due to water penetration, built-in moisture, and interstitial condensation. In this work, breathable composite membranes were prepared using micro-fibrillated cellulose fiber (CF) and polylactic acid (PLA). The chemical composition and physical structure of CF is responsible for its hydrophilic nature, which affects its compatibility with polymers and consequently its performance in the presence of excessive moisture conditions. To enhance the dispersibility of CF in the PLA polymer, the fibers were treated with an organic phosphoric acid ester-based surfactant. The hygroscopic properties of the PLA-CF composites were improved after surfactant treatment and the membranes were resistant to water yet permeable to vapor. Morphological examination of the surface showed better interfacial adhesion and enhanced dispersion of CF in the PLA matrix. Thermal analysis revealed that the surfactant treatment of CF enhanced the glass transition temperature and thermal stability of the composite samples. These bio-based membranes have immense potential as durable, eco-friendly, weather resistant barriers for the building industry as they can adapt to varying humidity conditions, thus allowing entrapped water vapor to pass through and escape the building, eventually prolonging the building life.

19.
Materials (Basel) ; 14(8)2021 Apr 08.
Artigo em Inglês | MEDLINE | ID: mdl-33917890

RESUMO

The main goal of this study was to review current studies on the state of the art of wood constructions with a particular focus on energy efficiency, which could serve as a valuable source of information for both industry and scholars. This review begins with an overview of the role of materials in wood buildings to improve energy performance, covering structural and insulation materials that have already been successfully used in the market for general applications over the years. Subsequently, studies of different wood building systems (i.e., wood-frame, post-and-beam, mass timber and hybrid constructions) and energy efficiency are discussed. This is followed by a brief introduction to strategies to increase the energy efficiency of constructions. Finally, remarks and future research opportunities for wood buildings are highlighted. Some general recommendations for developing more energy-efficient wood buildings are identified in the literature and discussed. There is a lack of emerging construction concepts for wood-frame and post-and-beam buildings and a lack of design codes and specifications for mass timber and hybrid buildings. From the perspective of the potential environmental benefits of these systems as a whole, and their effects on energy efficiency and embodied energy in constructions, there are barriers that need to be considered in the future.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA